Dr. Wesolowski on Home Administration of Fixed-Dose Pertuzumab/Trastuzumab Plus Chemo in Early Stage HER2+ Breast Cancer

April 30, 2021
Robert Wesolowski, MD

Robert Wesolowski, MD, discusses the possibility of home administration of fixed dose pertuzumab and trastuzumab plus chemotherapy in patients with HER2-positive early breast cancer.

Robert Wesolowski, MD, a medical oncologist and associate professor-clinical at The Ohio State University Comprehensive Cancer Center, discusses the possibility of home administration of fixed dose pertuzumab (Perjeta) and trastuzumab (Herceptin) plus chemotherapy in patients with HER2-positive early breast cancer.

The regimen was examined in the phase 3 FeDeriCa (NCT03493854) trial and is ideal for patients who have poor intravenous access, who do not have a port, or who wish to remove their port, according to Wesolowski. However, the concept of home administration with the combination is controversial, as many providers are not comfortable with the idea of patients receiving the treatment at home, he says.

Motivated, reliable patients may be a good fit for this treatment strategy, especially since they will continue to be monitored by a healthcare professional regardless of whether the administration is done at home, Wesolowski concludes.